Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Notable movers of interest: A +4.3% on upgrade to Overweight from Equal-Weight at Morgan Stanley<p>The following are some of today's most notable movers of interest, categorized by market capitalization (large cap over $10 billion and mid cap between $2-10 billion) and ranked by % change (all stocks over 100K average daily volume).</p><p><strong>Large Cap Gainers</strong></p><ul><li><strong>A</strong> (54.44 +4.27%): Upgraded to Overweight from Equal-Weight at Morgan Stanley.</li><li><strong>ANTM</strong> (170.31 +3.11%): Reaffirms FY17 adj EPS guidance to be greater than $11.50/share in an 8-K.</li><li><strong>HOG</strong> (61.86 +2.93%): Upgraded to Neutral from Underperform at Longbow.</li></ul><p><strong>Large Cap Losers</strong></p><ul><li><strong>TWTR</strong> (14.97 -2.32%): Early investor and long-time advocate Chris Sacca in series of tweets says no longer a shareholder, 'love the service, hate the stock'.</li><li><strong>ESRX</strong> (65.65 -1.78%): Downgraded to Underperform from Market Perform at Wells Fargo.</li><li><strong>NSC</strong> (116.96 -1.17%): Downgraded to Peer Perform from Outperform at Wolfe Research.</li></ul><p><strong>Mid Cap Gainers</strong></p><ul><li><strong>MSCI</strong> (105.76 +9.79%): Reports that S&P Global might be considering a GBP 9 bln takeover of the company.</li><li><strong>CLVS</strong> (72.71 +8.6%): Extends yesterday's strength after Astra-Zeneca's (<strong><strong>AZN</strong></strong>) positive PARP inhibitor data yesterday. Tesaro's (<strong><strong>TSRO</strong></strong>) PARP inhibitor was thought to be the best (and a potential prized asset to an acquirer) up until yesterday. AZN's positive data seems to have put the all three PARP assets (CLVS, TSRO and AZN) on somewhat of a level playing field, making CLVS look relatively more attractive.</li></ul><p><strong>Mid Cap Losers</strong></p><ul><li><strong>TSRO</strong> (150.83 -1.84%): Tesaro target lowered to $164 from $200 at Wedbush after Lynparza demonstrates similar top-line efficacy in maintenance therapy SOLO-2 study.</li><li><strong>ON</strong> (15.09 -1.73%): Prices offering of $500 mln of 1.625% Convertible Senior Notes due 2023.</li><li><strong>VRX</strong> (10.81 -0.73%): Shares trade lower on continued weakness following yesterdays selloff on news that Pershing Square has sold their entire stake.</li></ul></td> </tr></table>"